Which has better earnings & valuation, HYPR or NEPH?

Nephros has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 12.02 -$35.57M -$0.41 N/A Nephros $18.79M 1.98 $1.19M $0.07 48.86

Is HYPR or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Hyperfine's net margin of -226.88%. Nephros' return on equity of 7.66% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -226.88% -98.83% -67.09% Nephros 4.06% 7.66% 5.86%

Is NEPH or GUTS more profitable?

Nephros has a net margin of 4.06% compared to Fractyl Health's net margin of 0.00%. Nephros' return on equity of 7.66% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Fractyl Health N/A -4,053.15% -96.41%

Which has better earnings and valuation, NEPH or SNWV?

Sanuwave Health has higher revenue and earnings than Nephros. Sanuwave Health is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 1.98 $1.19M $0.07 48.86 Sanuwave Health $44.05M 2.88 $11.81M $0.33 44.73

Is NEPH or SNWV more profitable?

Sanuwave Health has a net margin of 35.96% compared to Nephros' net margin of 4.06%. Nephros' return on equity of 7.66% beat Sanuwave Health's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Sanuwave Health 35.96% -450.56% 44.87%

Is RCEL or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Avita Medical's net margin of -62.67%. Nephros' return on equity of 7.66% beat Avita Medical's return on equity. Company Net Margins Return on Equity Return on Assets Avita Medical -62.67% N/A -78.92% Nephros 4.06% 7.66% 5.86%

Which has better earnings & valuation, HSDT or NEPH?

Nephros has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solana $9.59M 7.73 -$40.89M -$109.67 N/A Nephros $18.79M 1.98 $1.19M $0.07 48.86

Is HSDT or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Solana's net margin of -1,427.15%. Nephros' return on equity of 7.66% beat Solana's return on equity. Company Net Margins Return on Equity Return on Assets Solana -1,427.15% -67.57% -24.09% Nephros 4.06% 7.66% 5.86%

Nephros (NEPH) Competitors

$3.42 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$3.40 -0.02 (-0.58%)

As of 04:00 AM Eastern

Compare

NEPH vs. HYPR, GUTS, SNWV, RCEL, and HSDT

Should you buy Nephros stock or one of its competitors? MarketBeat compares Nephros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nephros include Hyperfine (HYPR), Fractyl Health (GUTS), Sanuwave Health (SNWV), Avita Medical (RCEL), and Solana (HSDT). These companies are all part of the "medical equipment" industry.

How does Nephros compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Hyperfine had 2 more articles in the media than Nephros. MarketBeat recorded 2 mentions for Hyperfine and 0 mentions for Nephros. Nephros' average media sentiment score of 0.76 beat Hyperfine's score of 0.42 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperfine	Neutral
Nephros	Positive

Hyperfine has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nephros has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.02	-$35.57M	-$0.41	N/A
Nephros	$18.79M	1.98	$1.19M	$0.07	48.86

Hyperfine presently has a consensus target price of $1.78, suggesting a potential upside of 29.23%. Nephros has a consensus target price of $6.00, suggesting a potential upside of 75.44%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nephros has a net margin of 4.06% compared to Hyperfine's net margin of -226.88%. Nephros' return on equity of 7.66% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Nephros	4.06%	7.66%	5.86%

Summary

Nephros beats Hyperfine on 12 of the 16 factors compared between the two stocks.

How does Nephros compare to Fractyl Health?

Nephros (NASDAQ:NEPH) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Nephros has a net margin of 4.06% compared to Fractyl Health's net margin of 0.00%. Nephros' return on equity of 7.66% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Fractyl Health	N/A	-4,053.15%	-96.41%

41.1% of Nephros shares are held by institutional investors. 6.7% of Nephros shares are held by company insiders. Comparatively, 8.5% of Fractyl Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nephros has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

Nephros has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	1.98	$1.19M	$0.07	48.86
Fractyl Health	N/A	N/A	-$140.95M	-$1.29	N/A

In the previous week, Fractyl Health had 3 more articles in the media than Nephros. MarketBeat recorded 3 mentions for Fractyl Health and 0 mentions for Nephros. Nephros' average media sentiment score of 0.76 beat Fractyl Health's score of 0.00 indicating that Nephros is being referred to more favorably in the media.

Company	Overall Sentiment
Nephros	Positive
Fractyl Health	Neutral

Nephros presently has a consensus price target of $6.00, indicating a potential upside of 75.44%. Fractyl Health has a consensus price target of $5.40, indicating a potential upside of 695.76%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Nephros beats Fractyl Health on 10 of the 15 factors compared between the two stocks.

How does Nephros compare to Sanuwave Health?

Nephros (NASDAQ:NEPH) and Sanuwave Health (NASDAQ:SNWV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

41.1% of Nephros shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 14.4% of Sanuwave Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Nephros' average media sentiment score of 0.76 beat Sanuwave Health's score of 0.00 indicating that Nephros is being referred to more favorably in the media.

Company	Overall Sentiment
Nephros	Positive
Sanuwave Health	Neutral

Sanuwave Health has higher revenue and earnings than Nephros. Sanuwave Health is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	1.98	$1.19M	$0.07	48.86
Sanuwave Health	$44.05M	2.88	$11.81M	$0.33	44.73

Nephros currently has a consensus target price of $6.00, indicating a potential upside of 75.44%. Sanuwave Health has a consensus target price of $51.00, indicating a potential upside of 245.53%. Given Sanuwave Health's higher possible upside, analysts plainly believe Sanuwave Health is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Nephros has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Sanuwave Health has a net margin of 35.96% compared to Nephros' net margin of 4.06%. Nephros' return on equity of 7.66% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Sanuwave Health	35.96%	-450.56%	44.87%

Summary

Sanuwave Health beats Nephros on 10 of the 14 factors compared between the two stocks.

How does Nephros compare to Avita Medical?

Avita Medical (NASDAQ:RCEL) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Avita Medical has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 2.8% of Avita Medical shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nephros has lower revenue, but higher earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$72.35M	1.78	-$48.59M	-$1.57	N/A
Nephros	$18.79M	1.98	$1.19M	$0.07	48.86

Nephros has a net margin of 4.06% compared to Avita Medical's net margin of -62.67%. Nephros' return on equity of 7.66% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-62.67%	N/A	-78.92%
Nephros	4.06%	7.66%	5.86%

Avita Medical currently has a consensus price target of $7.25, indicating a potential upside of 73.44%. Nephros has a consensus price target of $6.00, indicating a potential upside of 75.44%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Avita Medical had 6 more articles in the media than Nephros. MarketBeat recorded 6 mentions for Avita Medical and 0 mentions for Nephros. Avita Medical's average media sentiment score of 1.10 beat Nephros' score of 0.76 indicating that Avita Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Avita Medical	Positive
Nephros	Positive

Summary

Nephros beats Avita Medical on 11 of the 16 factors compared between the two stocks.

How does Nephros compare to Solana?

Solana (NASDAQ:HSDT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

18.6% of Solana shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Solana presently has a consensus target price of $3.50, indicating a potential upside of 175.59%. Nephros has a consensus target price of $6.00, indicating a potential upside of 75.44%. Given Solana's higher probable upside, equities research analysts plainly believe Solana is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nephros has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$9.59M	7.73	-$40.89M	-$109.67	N/A
Nephros	$18.79M	1.98	$1.19M	$0.07	48.86

Nephros has a net margin of 4.06% compared to Solana's net margin of -1,427.15%. Nephros' return on equity of 7.66% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
Nephros	4.06%	7.66%	5.86%

In the previous week, Nephros' average media sentiment score of 0.76 beat Solana's score of 0.00 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Solana	Neutral
Nephros	Positive

Solana has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Summary

Nephros beats Solana on 10 of the 14 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEPH vs. The Competition

Export

Metric	Nephros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.14M	$8.33B	$6.46B	$11.98B
Dividend Yield	N/A	2.52%	2.67%	5.55%
P/E Ratio	48.86	16.14	23.90	23.62
Price / Sales	1.98	6.26	483.49	89.64
Price / Cash	27.26	17.45	26.99	37.25
Price / Book	3.56	3.57	10.34	6.66
Net Income	$1.19M	$225.32M	$3.57B	$337.72M
7 Day Performance	-7.32%	-1.06%	-0.93%	-3.74%
1 Month Performance	-2.84%	2.11%	3.54%	0.95%
1 Year Performance	1.79%	-3.59%	23.79%	25.35%

Nephros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEPH Nephros	2.7858 of 5 stars	$3.42 flat	$6.00 +75.4%	+1.8%	$37.14M	$18.79M	48.86	30	Gap Up
HYPR Hyperfine	3.0396 of 5 stars	$1.66 +11.4%	$1.78 +7.4%	+73.3%	$147.91M	$11.40M	N/A	190	High Trading Volume
GUTS Fractyl Health	2.0498 of 5 stars	$0.92 +0.9%	$5.40 +488.4%	-65.9%	$144.31M	N/A	N/A	102	Gap Up
SNWV Sanuwave Health	1.6538 of 5 stars	$16.26 -2.6%	$51.00 +213.7%	-47.1%	$143.52M	$44.05M	49.27	40	Gap Up
RCEL Avita Medical	3.3726 of 5 stars	$4.25 -7.2%	$7.25 +70.6%	-31.6%	$140.96M	$72.35M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEPH) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephros (NEPH) Competitors

NEPH vs. HYPR, GUTS, SNWV, RCEL, and HSDT

How does Nephros compare to Hyperfine?

Summary

How does Nephros compare to Fractyl Health?

Summary

How does Nephros compare to Sanuwave Health?

Summary

How does Nephros compare to Avita Medical?

Summary

How does Nephros compare to Solana?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nephros (NEPH) Competitors

NEPH vs. HYPR, GUTS, SNWV, RCEL, and HSDT

How does Nephros compare to Hyperfine?

Does the media refer more to HYPR or NEPH?

Which has more risk & volatility, HYPR or NEPH?

Do insiders and institutionals hold more shares of HYPR or NEPH?

Which has better earnings & valuation, HYPR or NEPH?

Do analysts recommend HYPR or NEPH?

Is HYPR or NEPH more profitable?

Summary

How does Nephros compare to Fractyl Health?

Is NEPH or GUTS more profitable?

Do insiders and institutionals have more ownership in NEPH or GUTS?

Which has more volatility and risk, NEPH or GUTS?

Which has stronger valuation & earnings, NEPH or GUTS?

Does the media refer more to NEPH or GUTS?

Do analysts recommend NEPH or GUTS?

Summary

How does Nephros compare to Sanuwave Health?

Do insiders & institutionals have more ownership in NEPH or SNWV?

Does the media prefer NEPH or SNWV?

Which has better earnings and valuation, NEPH or SNWV?

Do analysts recommend NEPH or SNWV?

Which has more volatility & risk, NEPH or SNWV?

Is NEPH or SNWV more profitable?

Summary

How does Nephros compare to Avita Medical?

Which has more risk and volatility, RCEL or NEPH?

Do insiders and institutionals believe in RCEL or NEPH?

Which has stronger valuation and earnings, RCEL or NEPH?

Is RCEL or NEPH more profitable?

Do analysts prefer RCEL or NEPH?

Does the media favor RCEL or NEPH?

Summary

How does Nephros compare to Solana?

Do institutionals & insiders believe in HSDT or NEPH?

Do analysts prefer HSDT or NEPH?

Which has better earnings & valuation, HSDT or NEPH?

Is HSDT or NEPH more profitable?

Does the media refer more to HSDT or NEPH?

Which has more risk & volatility, HSDT or NEPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools